Nephrology
Latest news
138 articles · 20 / page
Impact of Dietary Patterns on the Progression of Chronic Kidney Disease in Cardio-Metabolic Disorders: Insights from Multi-State Models in a Large UK Cohort
This study reveals that adherence to the American Heart Association diet significantly reduces CKD progression risk from cardio-metabolic disorders, underscoring its role in early intervention strategies.
Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib
This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.
Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program
A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.
Enhancing Cardiovascular Health in Kidney Transplant Recipients: Updated Evidence on Physical Activity Interventions
An updated meta-analysis of 23 RCTs reveals that physical activity improves cardiorespiratory fitness and HDL cholesterol in adult kidney transplant recipients, suggesting important cardiovascular benefits despite current study limitations.
Reassessing the Role of Steroidal Mineralocorticoid Receptor Antagonists in Dialysis Patients: Safety and Efficacy Insights from a Systematic Review and Meta-Analysis
Steroidal mineralocorticoid receptor antagonists show minimal impact on cardiovascular mortality in dialysis patients, with limited safety concerns and evidence gaps in subgroups and non-steroidal agents.
Balancing Risks and Benefits: Individual Data Analysis of Intensive vs. Standard Blood Pressure Control on Cardiovascular and Renal Outcomes
A large pooled analysis shows that intensive blood pressure control reduces cardiovascular events with a modest increase in adverse effects, resulting in an overall net clinical benefit.
Oral Iptacopan Shows Promise in Reducing Proteinuria in C3 Glomerulopathy: Results from a Global Phase 3 Trial
The APPEAR-C3G phase 3 trial demonstrates that oral iptacopan significantly reduces proteinuria and is well tolerated in adults with C3 glomerulopathy, an ultra-rare glomerulonephritis linked to alternative complement pathway overactivation
Evaluating Cost-Effectiveness of Accelerated Versus Standard Initiation of Renal Replacement Therapy in Severe Acute Kidney Injury
This analysis reveals that standard initiation of kidney replacement therapy (KRT) in critically ill patients with severe acute kidney injury (AKI) offers greater quality-adjusted life years (QALYs) at an acceptable increased cost, suggesti
Sustained Cardiovascular Health in Young Adulthood Significantly Reduces Midlife Cardiovascular and Kidney Risks
A high cumulative cardiovascular health score from ages 30 to 40 correlates with substantially lower risks of cardiovascular and kidney events in midlife, underscoring the impact of early-life prevention strategies.
Exploring the Impact of Reduced Left Ventricular Function on Outcomes After PCI in Chronic Kidney Disease Patients
Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall
Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial
This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise fo
Lubiprostone Therapy in Chronic Kidney Disease: A Phase 2 Trial Reveals Mitochondrial Enhancement via Polyamine Modulation
A phase 2 randomized trial in CKD patients shows lubiprostone preserves renal function by modulating gut microbiota polyamine pathways and improving mitochondrial health, independent of uremic toxin levels, offering a novel therapeutic aven
Flexovital Food Supplement Shows Promise in Mitigating Cardiovascular-Kidney-Metabolic Syndrome in Preclinical Model
Flexovital, a nitric oxide-enhancing supplement, effectively attenuates metabolic, cardiovascular, and renal dysfunctions in a mouse model of cardiovascular-kidney-metabolic syndrome induced by unilateral nephrectomy and Western diet.
Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence
This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone’s efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing future dire
Spironolactone in Chronic Haemodialysis Patients: Insights from the ALCHEMIST Trial and Updated Meta-Analysis
The ALCHEMIST trial reveals spironolactone does not improve cardiovascular outcomes in high-risk chronic haemodialysis patients, aligning with a meta-analysis that challenges the benefit of mineralocorticoid receptor antagonists in this pop
Silent Threats: Why Uremia is Affecting Younger Adults and How to Protect Your Kidneys
Uremia, the deadly end-stage of kidney disease, is increasingly diagnosed in younger adults. Early detection and lifestyle changes can prevent progression. This article explores risk factors, symptoms, diagnosis, treatment options, and prev
Case Report: Unilateral Renal Agenesis Presenting as Recurrent Urinary Tract Infections in a 25-Year-Old Woman
A 25-year-old woman with recurrent urinary tract infections was diagnosed with unilateral renal agenesis, highlighting the importance of imaging in persistent urinary symptoms.
Epaminurad: A Promising hURAT1 Inhibitor for Effective and Safe Gout Management – Insights from a Phase 2b Dose-Finding Trial
Epaminurad significantly lowers serum urate levels in gout patients with excellent safety, offering a promising alternative to existing therapies. This randomized controlled trial identifies optimal dosing and confirms tolerability over 12
Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept
Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-
Browse by specialty
Open language-specific specialty feeds and department pages.